AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
SLQT

SelectQuote Inc. Common Stock (SLQT) fair value

Financial Services · Insurance Brokers · NYSE · United States
$0.31-7.51%
Market cap $55MNext earnings 2026-11-04Updated Oct 22, 2026
Add earnings to calendarGoogle
Our verdict
Trades 79% below our fair value
Price
$0.31
Model fair valueConfidence: low
about $1.51
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a growth company: Discounted cash flow.
ACCE opinionSelectQuote Inc. Common Stock (SLQT)
Fair value
Not available
ACCE price target
$0.32
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $0.31 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
41
out of 100
Analysts
50% buy
4 covering
1-year return
-84.5%
Dividend yield
0.00%

SelectQuote Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

SelectQuote is a Medicare-focused insurance distribution business: its agents sell Medicare Advantage and Part D plans for carriers and earn commissions, with a smaller direct-to-consumer and senior health-care services arm. The attraction is the franchise's scale in senior health enrollment and its gross margin of 35.6%, which shows the platform still earns real revenue per policy. The problem is the top line, with revenue down 6.8% and an operating margin of just 1.1%, so almost none of that gross margin reaches operating profit. The ROE of 10.2% and a forward P/E of 66.7 point to earnings that are both thin and expected to be rebuilt, with a 61M market cap leaving a very small equity base for that uncertainty. The score of 41/100 and absence from any index suggest the market has not warmed to the story, so this deserves a look only if you believe Medicare enrollment economics can convert to operating profit.

AI-assisted·How I use AIWritten Oct 18, 2026

Next results

Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where SLQT's valuation models land
Price
$0.31
Model fair valueConfidence: low
about $1.51
Model
Fair value
Upside
Discounted cash flow
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Mixed50% buy · 4 covering analysts
● Strong buy 2● Buy 0● Hold 2● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-3.1%
1 month
-27.9%
3 months
-51.6%
6 months
-65.9%
YTD
-78.0%
1 year
-84.5%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
15 Oct 2026, 00:00 CESTACCE price target$0.32first publication$0.35

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full SLQT page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth43Value57Quality47Momentum17Total41
Valuation
Trailing P/E
no data
Forward P/E
15.3x
PEG
no data
P/B
0.22x
EV / Revenue
0.5x
Book value/sh
$1.99
Enterprise value
$755M
Profitability
ROE
10.2%
FCF yield
45.30%
ROIC
4.9%
Health and risk
Debt / equity
0.61
Dividend yield
0.00%
Beta
1.94

Price

-85.0% · 1Y

Ask anything about SLQT

Answered from SelectQuote Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
ROEbetter than 67% of peers
low -112%10%high 83%
Div yieldbetter than 100% of peers
low 0.0%0.0%high 0.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
SLQT SelectQuote Inc. Common Stock$0.31---10.2%4741
AIFU AIFU Inc. Class A Ordinary Share$11.33----112.3%5634
HUIZ Huize Holding Limited American Depositary Shares$2.26--7.4x5.3%4751
EHTH eHealth Inc. Common Stock$0.55---2.9%5436
XHG XChange TEC.INC American Depositary Shares $3.80--0.0x0.0%1656
TWFG TWFG Inc. Class A Common Stock$28.67$269% above44.8x19.3%8282
TREE LendingTree Inc. Common Stock$27.56$6155% below2.1x82.8%7163

Sector report card

Where SLQT ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Oct 14, 2026
    SelectQuote to Release Fiscal First Quarter 2027 Earnings on November 4
  • PR Newswire•Oct 13, 2026
    Savus Strengthens Platform Engineering with Senior Hire from SelectQuote and Wells Fargo
  • Business Wire•Aug 25, 2026
    SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2026 Results
1 more press releases · full archive on Investor+.INVESTOR
31 filings of 40
September 2026
Sep 30
ProxyProxy statementPeriod 2026-11-10
View on SEC →
August 2026
Aug 25
10-KAnnual reportPeriod 2026-06-30
View on SEC →
Aug 25
8-KCurrent reportPeriod 2026-08-25
View on SEC →
28 more filings + AI summaries on Investor+.INVESTOR